The impact of XXXX status at the time of HLA-identical sibling marrow transplantation on subsequent complication rate and survival of adults with @entity3052 .

@entity1 @entity981 @entity786 @entity3052 @entity1778 @entity2132 @entity348 @entity401
Between March 1981 and March 1985, 76 @entity1 with @entity3052 were treated with @entity786 (120 mg/kg), 12 or 14 @entity348 , and an HLA-identical sibling marrow transplant. Forty-seven @entity1 had @entity981 ( @entity981 ) and 29 had @entity981 ( @entity981 ). Forty-one were transplanted during first remission and 28 during or after first relapse of their disease. An additional six @entity1 were transplanted because their @entity1778 was refractory to conventional cytotoxic chemotherapy, and one was transplanted as initial therapy. Actuarial 42 month survival for those transplanted during first remission was 47% and for those transplanted in first relapse or later it was 22% (p = 0.02). There was no difference in either group between those with @entity981 and those with @entity981 . Two of the six @entity1 with @entity1778 are alive more than 22 and more than 15 months after the transplant. The incidence of @entity2132 and @entity401 was 90% and 39%, respectively, for the first remission group, and 96% and 37% for those transplanted in first relapse or later. There was no significant difference in transplant-related mortality between the two groups (29% and 43%, respectively). The @entity1778 recurrence rate, however, was 13% for those transplanted in first remission and 67% for those transplanted in first relapse or later (p = 0.0003). Thus, the major factor determining the incidence of @entity1778 recurrence and survival after transplant was the status of the @entity1778 at the time of transplantation.(ABSTRACT TRUNCATED AT 250 WORDS)
